Brian Till, M.D.

faculty member

Brian Till, M.D.

Associate Member
Clinical Research Division, Fred Hutch

Fax: 206.667.1874
Mail Stop: D3-100

Dr. Brian Till develops new treatments for lymphoma by genetically engineering a patient's own T cells so they can more effectively attack cancer. T cells target and kill cancer cells by binding to specific proteins on the tumor cells with molecules called T-cell receptors. Dr. Till's research involves making synthetic receptors known as chimeric antigen receptors, or CARs, that home in on lymphoma cells. He led the first published trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till continues to carry out a variety of immunological, genetic and gene-expression studies in the clinic to understand why CAR T-cell therapies work for some patients and fail for others. This research will help improve the next iterations of this experimental therapy.

Other Appointments & Affiliations

Associate Professor of Medicine
University of Washington

Attending Physician, Stem Cell Transplant Service
Seattle Cancer Care Alliance

Attending Physician, Immunotherapy Service
Seattle Cancer Care Alliance

Education

B.S., Biology, The Catholic University of America, Washington, DC, 1998

M.D., University of Chicago, 2002

Resident, Internal Medicine, Hospital of the University of Pennsylvania, 2002-2005

Senior Fellow, Medical Oncology, Fred Hutchinson Cancer Research Center and UW, 2005-2008

Research Associate, Fred Hutchinson Cancer Research Center, 2008-2011